Please use this identifier to cite or link to this item:
https://doi.org/10.1155/2010/435745
Title: | Cytokine-induced NK-like T cells: From bench to bedside | Authors: | Hui, K.M Linn, Y.C |
Keywords: | carbon tetrachloride CD27 antigen CD28 antigen CD3 antigen CD56 antigen chemokine receptor CCR1 chemokine receptor CXCR3 cytokine gamma interferon interleukin 12 receptor beta2 interleukin 1beta converting enzyme interleukin 7 receptor L selectin macrophage inflammatory protein 1alpha RANTES tumor necrosis factor alpha acute granulocytic leukemia acute lymphoblastic leukemia allograft animal experiment antineoplastic activity cancer cell culture cancer immunotherapy chronic lymphatic leukemia chronic myeloid leukemia cytokine induced killer cell cytolysis cytotoxicity donor lymphocyte infusion effector cell genetic transfection genotype graft versus host reaction graft versus leukemia effect immunophenotyping in vitro study major histocompatibility complex memory T lymphocyte mouse multiple myeloma nonhuman ovary carcinoma phenotype review T lymphocyte subpopulation Th1 cell tumor cell adoptive immunotherapy animal biotechnology human immunology leukemia lymphoma methodology Animals Biotechnology Cytokine-Induced Killer Cells Humans Immunotherapy, Adoptive Leukemia Lymphoma |
Issue Date: | 2010 | Citation: | Hui, K.M, Linn, Y.C (2010). Cytokine-induced NK-like T cells: From bench to bedside. Journal of Biomedicine and Biotechnology 2010 : 435745. ScholarBank@NUS Repository. https://doi.org/10.1155/2010/435745 | Rights: | Attribution 4.0 International | Abstract: | Cytokine-induced killer (CIK) cells are polyclonal T effector cells generated when cultured under cytokine stimulation. CIK cells exhibit potent, non-MHC-restricted cytolytic activities against susceptible tumor cells of both autologous and allogeneic origins. Over the past 20 years, CIK cells have evolved from experimental observations into early clinical studies with encouraging preliminary efficacy towards susceptible autologous and allogeneic tumor cells in both therapeutic and adjuvant settings. This paper is our attempt to summarize the available published literature related to CIK cells. Looking into the future, we anticipate that the continuous therapeutic application of CIK cells will likely be developed along two major directions: overcoming the challenge to organize large prospective randomized clinical trials to define the roles of CIK cells in cancer immunotherapy and expanding its spectrum of cytotoxicity towards resistant tumor cells through experimental manipulations. © 2010 Y. C. Linn and K. M. Hui. | Source Title: | Journal of Biomedicine and Biotechnology | URI: | https://scholarbank.nus.edu.sg/handle/10635/180990 | ISSN: | 1110-7243 | DOI: | 10.1155/2010/435745 | Rights: | Attribution 4.0 International |
Appears in Collections: | Staff Publications Elements |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_1155_2010_435745.pdf | 1.25 MB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License